Would you offer Durvalumab as consolidation therapy to a patient with stage III NSCLC but had local recurrence treated with definitive SBRT?

When would you offer consolidation durvalumab after a local recurrence of stage III NSCLC?

• Never
• For a nodal or parenchymal failure after local therapy, regardless of PD-L1 status
• For a nodal failure only after local therapy, regardless of PD-L1 status
• For a nodal or parenchymal failure after local therapy, if PD-L1 > 1%
• For a nodal failure only after local therapy, if PD-L1> 1%
• Other